BBR Partners’s UroGen Pharma URGN Stock Holding History

BBR Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,000	Closed	-$390K	–	263
2024 Q1	$390K	Hold	26,000	–	–	0.03%	162
2023 Q4	$390K	Hold	26,000	–	–	0.04%	120
2023 Q3	$364K	Hold	26,000	–	–	0.04%	130
2023 Q2	$269K	Hold	26,000	–	–	0.03%	132
2023 Q1	$240K	Hold	26,000	–	–	0.03%	139
2022 Q4	$231K	Hold	26,000	–	–	0.03%	155
2022 Q3	$216K	Hold	26,000	–	–	0.03%	151
2022 Q2	$213K	Sell	26,000 -17,000	-40%	-$117K	0.02%	196
2022 Q1	$375K	Buy	+43,000	New	+$335K	0.04%	161

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBR Partners's URGN Position: Q2 2024 in Review

BBR Partners sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 26,000 shares — an estimated $390K sold.

BBR Partners first reported a position in URGN in Q1 2022 and held it in 9 quarters. The position peaked at $390K in Q1 2024. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

BBR Partners reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
BBR Partners sold 26,000 UroGen Pharma shares in Q2 2024, an estimated $390K.
BBR Partners first reported a position in UroGen Pharma in Q1 2022 and held it in 9 quarters.
BBR Partners's UroGen Pharma position peaked at $390K in Q1 2024.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on BBR Partners's 13F filing for Q2 2024, filed 5 Aug 2024.